ITCI Intra-Cellular Therapies Inc.

12.48
+0.22  (+2%)
Previous Close 12.26
Open 12.22
Price To Book 2.17
Market Cap 687856903
Shares 55,116,739
Volume 282,883
Short Ratio
Av. Daily Volume 310,897

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data due 2Q 2019.
ITI-007 - Monotherapy (Study 401)
Bipolar depression
Phase 3 interim analysis December 18, 2018 noted trial to stop due to futility.
ITI-007-201
Agitation in patients with dementia
PDUFA date September 27, 2019.
Lumateperone
Schizophrenia
Phase 3 enrollment to be completed 2H 2019.
ITI-007 - Adjunctive Therapy
Bipolar depression
Phase 3 top-line data due 2Q 2019.
ITI-007 - Monotherapy (Study 404)
Bipolar depression
Phase 1/2 top-line presented October 22, 2018.
ITI-214
Parkinson's disease (PD)

Latest News

  1. Intra-Cellular Therapies Mourns the Passing of Co-Founder and Nobel Laureate, Dr. Paul Greengard
  2. Intra-Cellular Therapies Presents Additional Results From Long-term Open Label Safety Study of Lumateperone at the 2019 Congress of the Schizophrenia International Research Society
  3. Investors Who Bought Intra-Cellular Therapies (NASDAQ:ITCI) Shares Three Years Ago Are Now Down 61%
  4. Intra-Cellular Therapies Continues to Strengthen Its Commercial Leadership Team; John A. Bardi Appointed as Senior Vice President, Market Access, Policy and Government Affairs
  5. Intra-Cellular Therapies to Present at The Cowen and Company 39th Annual Health Care Conference
  6. Edited Transcript of ITCI earnings conference call or presentation 27-Feb-19 1:30pm GMT
  7. Intra-Cellular Therapies Inc (ITCI) Q4 2018 Earnings Conference Call Transcript
  8. Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
  9. Intra-Cellular Therapies to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  10. Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast
  11. Detailed Research: Economic Perspectives on Tesla, Kura Oncology, ASML Holding N.V, Applied Industrial Technologies, Raven Industries, and Intra-Cellular Therapies — What Drives Growth in Today's Competitive Landscape
  12. Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst
  13. Read This Before Buying Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares
  14. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI
  15. Intra-Cellular Therapies to Present at the 37th Annual J.P. Morgan Healthcare Conference
  16. Is Intra-Cellular Therapies Inc (ITCI) A Good Stock To Buy?
  17. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Intra-Cellular Therapies, Inc. (ITCI)